ClinicalTrials.gg
CompletedNCT01583374POSTUREUpdated May 12, 2020Results posted

Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis

A Phase 3 interventional study of Apremilast tablet 20 mg and Apremilast tablet 30 mg BID in Ankylosing Spondyloarthritis, sponsored by Amgen. Completed at 103 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-12.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
490
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Spondylitis, Ankylosing with a site in United States — 10 open to participants now, 13 under way, none of them phase 3. Spondylitis, Ankylosing · United States.

Enrollment
8th of 59
490 · median 223
Started
2012
with 2 others
Phase 3
25 of 87
none open now
Registered
25th of 87
by date
Lead sponsor
2 of 87
Amgen

Among the 87 studies in Spondylitis, Ankylosing with a site in United States, this one is the 8th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2012, is one of 25 in phase 3, and was the 25th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

10 of the 87 studies in Spondylitis, Ankylosing with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Spondylitis, Ankylosing with a site in United States, or all of them as a file.
02

Study summary

Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.

Read the detailed description

Patients were randomized in a 1:1:1 ratio to placebo, apremilast 20 mg BID and apremilast 30 mg BID. The duration of the study was approximately 5 years. The double blind period (when patients nor the physician knew whether placebo or apremilast was taken) was 24 weeks. At Week 16, participants who did not have either a ≥ 20% improvement or a ≥ 1 unit improvement from baseline in at least two of the four SpondyloArthritis international Society (ASAS) domains were entered in "early escape" from their current treatment in a double-blinded manner. However, such participants were permitted to continue in the study. At Week 24, participants may have entered a long-term extension phase for up to an additional 4.5 years (236 weeks). At "second escape" (at Week 24), apremilast 20 mg BID treated participants transitioned to receive double-blinded apremilast 30 mg BID and remained on double-blinded apremilast 30 mg BID because they continued to improve with a longer duration of treatment. After Week 24 and during the early portion of the long-term extension through Week 52, all participants continued on either double-blinded apremilast 20 mg BID or 30 mg BID treatment. After all participants had completed Week 52 or had terminated early from the study and the 52-week data base was locked, apremilast 20 mg BID or 30 mg BID treatment was provided.

03

Conditions studied

  • Ankylosing Spondyloarthritis

Keywords

  • spondylitis
  • spondyloarthritis
  • Spondyloarthropathy
  • Oral preparation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a documented diagnosis of ankylosing spondylitis as defined by low back pain and stiffness, which improves with exercise, but is not relieved by rest for more than 3 months prior to screening. At the completion of screening procedures, a documented diagnosis of definite active AS, as defined by the modified New York criteria (1984) whereby both criteria, at least 1 radiographic criterion and at least 1 clinical criterion, must be met
  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is ≥ 4
  • Total back pain is ≥ 4
  • On stable dose of AS medication (or lack of medication) prior to randomization and through week 24

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a Tumor Necrosis Factor (TNF) blocker and any biologic treatment for AS
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
490 participants (actual)

Study arms

  • Experimental
    Apremilast 20 mg

    Apremilast 20 mg was taken orally twice a day (BID)

    Drug: Apremilast tablet 20 mg

  • Experimental
    Apremilast 30 mg

    Apremilast 30 mg was taken orally twice a day

    Drug: Apremilast tablet 30 mg BID

  • Placebo comparator
    Placebo

    Identically matched placebo tablets were taken orally twice a day

    Drug: Placebo

Interventions

  • Apremilast 20 mg was taken orally twice a day (BID)

    Also known as: Otezla; CC-10004

  • Apremilast 30 mg was taken orally twice a day

    Also known as: Otezla; CC-10004

  • DrugPlacebo

    Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16

    ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale \[NRS\]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index \[BASFI\] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24

    The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24

    The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.

    Time frame: Baseline and Week 24

  3. Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24

    ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale \[NRS\]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index \[BASFI\] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)

    Time frame: Baseline and Week 24

  4. Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24

    The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.

    Time frame: Baseline and Week 24

  5. Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement

    Time frame: Baseline and Week 24

  6. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24

    The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.

    Time frame: Baseline and Week 24

  7. Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260

    The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3. 0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.

    Time frame: Baseline to Week 104 and 260

  8. Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase

    A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.

    Time frame: From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.

  9. Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period

    A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.

    Time frame: Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks

07

Results

Posted Mar 17, 2015

Participant flow

The study enrolled participants at 88 study sites and in 18 countries (Australia, Austria, Bulgaria, Czech Republic, Estonia, France, Germany, Hungary, the Netherlands, Poland, Romania, Russia, Slovakia, Spain, the United Kingdom, Canada, Sweden, and the United States \[US\]).

Placebo-controlled Phase (Week 0-24)
Participant flow — Placebo-controlled Phase (Week 0-24)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 30 mg Early Escape (EE)Placebo/Apremilast 30 mg Crossover (XO)Apremilast 30 mg /Apremilast 30 mg EEApremilast 20 mg /Apremilast 30 mg EEApremilast 30 mg /Apremilast 30 mg Second Escape (SE)Apremilast 20 mg/Apremilast 30 mg SE
Started164163163000000
Received treatment164163163000000
Completed week 16150151144000000
Early escape at week 16514949000000
Completed145147138000000
Not completed191625000000
Withdrew: Adverse event6712000000
Withdrew: Lack of efficacy325000000
Withdrew: Non-compliance with study drug110000000
Withdrew: Withdrawal by subject835000000
Withdrew: Lost to follow-up120000000
Withdrew: Protocol violation003000000
Withdrew: Other010000000
Extension Phase (Weeks 24 to 52)
Participant flow — Extension Phase (Weeks 24 to 52)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 30 mg Early Escape (EE)Placebo/Apremilast 30 mg Crossover (XO)Apremilast 30 mg /Apremilast 30 mg EEApremilast 20 mg /Apremilast 30 mg EEApremilast 30 mg /Apremilast 30 mg Second Escape (SE)Apremilast 20 mg/Apremilast 30 mg SE
Started07465479148482523
Completed06961418543432221
Not completed054665532
Withdrew: Lost to follow-up000000010
Withdrew: Adverse event012011010
Withdrew: Lack of efficacy020632512
Withdrew: Non-compliance study drug021010000
Withdrew: Withdrawal by subject001012000
Long-Term Extension Phase Weeks 52-260
Participant flow — Long-Term Extension Phase Weeks 52-260
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo / Apremilast 30 mg Early Escape (EE)Placebo/Apremilast 30 mg Crossover (XO)Apremilast 30 mg /Apremilast 30 mg EEApremilast 20 mg /Apremilast 30 mg EEApremilast 30 mg /Apremilast 30 mg Second Escape (SE)Apremilast 20 mg/Apremilast 30 mg SE
Started06661358139382120
Completed04041225022201210
Not completed0262013311718910
Withdrew: Adverse event052262231
Withdrew: Lack of efficacy0467107424
Withdrew: Noncomplinace with study drug000010011
Withdrew: Withdrawal by subject011111127533
Withdrew: Death000010100
Withdrew: Lost to follow-up010110100
Withdrew: Miscellaneous051201501

Outcome measures

PrimaryPercentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16

ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale \[NRS\]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index \[BASFI\] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)

Time frame:
Baseline and Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16
Percentage of ParticipantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 1636.635.032.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.4383 · Risk difference (rd): -4.1 · 95% CI -14.3 to 6.2Adjusted difference is the weighted average of the treatment differences across the 4 strata of screening CRP category and baseline BASDAI score category with the Cochran-Mantel-Haenszel (CMH) weights
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.7427 · Risk difference (rd): -1.7 · 95% CI -12.0 to 8.5Adjusted difference in proportions is the weighted average of the treatment differences across the 4 strata of screening CRP category and baseline BASDAI score category with the Cochran-Mantel-Haenszel weights.
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24

The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24
Units on a ScalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24-0.94 ± 0.136-1.11 ± 0.137-0.99 ± 0.138
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.8032 · Ls mean difference: -0.05 · 95% CI -0.41 to 0.32Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.3624 · Ls mean difference: -0.17 · 95% CI -0.53 to 0.19Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24

The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24
Units on a ScalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24-1.21 ± 0.136-1.30 ± 0.136-1.18 ± 0.137
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.8618 · Ls mean difference: 0.03 · 95% CI -0.33 to 0.40Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.6262 · Ls mean difference: -0.09 · 95% CI -0.45 to 0.27Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
SecondaryPercentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24

ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale \[NRS\]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index \[BASFI\] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24
Percentage of ParticipantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 2431.736.233.7
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.6958 · Risk difference (rd): 2.0 · 95% CI -8.1 to 12.2Adjusted difference is the weighted average of the treatment differences across the 4 strata of screening CRP category and baseline BASDAI score category with the Cochran-Mantel-Haenszel weights.
  • Placebo vs Apremilast 20 mg · Cochran-Mantel-Haenszel · p = 0.4051 · Risk difference (rd): 4.4 · 95% CI -5.8 to 14.5Adjusted difference is the weighted average of the treatment differences across the 4 strata of screening CRP category and baseline BASDAI score category with the Cochran-Mantel-Haenszel weights.
SecondaryChange From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24

The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24
Units on a ScalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24-1.77 ± 0.278-1.50 ± 0.278-1.52 ± 0.281
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.5126 · Ls mean difference: 0.25 · 95% CI -0.49 to 0.99Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.4624 · Ls mean difference: 0.28 · 95% CI -0.46 to 1.01Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
SecondaryChange From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24
Units on a ScalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 243.50 ± 0.5533.46 ± 0.5513.79 ± 0.559
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.6997 · Ls mean difference: 0.29 · 95% CI -1.18 to 1.76Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.9587 · Ls mean difference: -0.04 · 95% CI -1.50 to 1.42Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24

The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24
Units on a ScalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24-0.19 ± 0.042-0.16 ± 0.043-0.13 ± 0.043
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.3307 · Ls mean difference: 0.06 · 95% CI -0.06 to 0.17Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.5938 · Ls mean difference: 0.03 · 95% CI -0.08 to 0.14Based on an ANCOVA model for change from baseline with treatment group, CRP and baseline BASDAI score as factors and baseline value as covariate.
SecondaryChange From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260

The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3. 0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.

Time frame:
Baseline to Week 104 and 260
Reported as:
Mean · Units on a Scale
Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260
Units on a ScaleApremilast 20 mgApremilast 30 mgPlacebo/Apremilast 30 mgApremilast 20 mg/ Apremilast 30 mgApremilast 20 mg/Apremilast 20 mg
Week 1040.99 ± 3.0180.65 ± 2.4530.98 ± 3.7680.82 ± 2.4351.12 ± 3.417
Week 2603.14 ± 8.2921.79 ± 6.9971.92 ± 7.3632.21 ± 5.9593.83 ± 9.652
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase

A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.

Time frame:
From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase
ParticipantsPlaceboApremilast 20 mgApremilast 30 mg
Any Treatment Emergent Adverse Event839188
Any Drug-related TEAE244451
Any Severe TEAE025
Any Serious TEAE136
Any Serious Drug-related TEAE003
Any TEAE Leading to Drug Interruption141314
Any TEAE Leading to Drug Withdrawal71113
Any TEAE Leading to Death000
SecondaryNumber of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period

A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.

Time frame:
Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period
ParticipantsApremilast 20 mgApremilast 20/30 mgApremilast 30 mg
Any Treatment Emergent Adverse Event11447239
Any Severe TEAE5823
Any Serious TEAE12841
Any TEAE Leading to Drug Interruption221151
Any TEAE Leading to Drug Withdrawal18434
Any TEAE Leading to Death011

Adverse events

Collected over AEs were reported for the placebo-controlled phase from Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants. AEs were reported for the apremilast (APR) exposure period from Week 0 to Week 260, irrespective of when the APR started (Week 0, 16 or 24). The median duration of treatment was 24, 163, and 216 weeks in the Apremilast 20 mg, Apremilast 20/30 mg and Apremilast 30 mg treatment groups respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Weeks 0-24) Placebo-Controlled Phase0/164 (0%)1/164 (0.6%)37/164 (22.6%)
Apremilast 20 mg BID (Weeks 0-24) Placebo-Controlled Phase0/163 (0%)3/163 (1.8%)58/163 (35.6%)
Apremilast 30 mg BID (Weeks 0-24) Placebo-Controlled Phase0/163 (0%)6/163 (3.7%)57/163 (35%)
Apremilast 20 mg BID (APR Exposure Period)0/163 (0%)12/163 (7.4%)82/163 (50.3%)
Apremilast 20/30 mg BID (APR Exposure Period)1/72 (1.4%)8/72 (11.1%)38/72 (52.8%)
Apremilast 30 mg BID (APR Exposure Period)1/305 (0.3%)41/305 (13.4%)168/305 (55.1%)
Most frequent serious events
Showing 10 of 73
Most frequent serious events
EventPlacebo (Weeks 0-24) Placebo-Controlled PhaseApremilast 20 mg BID (Weeks 0-24) Placebo-Controlled PhaseApremilast 30 mg BID (Weeks 0-24) Placebo-Controlled PhaseApremilast 20 mg BID (APR Exposure Period)Apremilast 20/30 mg BID (APR Exposure Period)Apremilast 30 mg BID (APR Exposure Period)
VertigoEar and labyrinth disorders0/1640/1631/1630/1631/721/305
IridocyclitisEye disorders0/1640/1630/1630/1631/721/305
VomitingGastrointestinal disorders0/1640/1630/1630/1631/720/305
Device failureGeneral disorders0/1640/1630/1630/1631/720/305
CholelithiasisHepatobiliary disorders0/1640/1630/1630/1631/720/305
Lower limb fractureInjury, poisoning and procedural complications0/1640/1630/1630/1631/720/305
Tibia fractureInjury, poisoning and procedural complications0/1640/1630/1630/1631/720/305
OsteoarthritisMusculoskeletal and connective tissue disorders0/1640/1630/1631/1631/721/305
Ischaemic strokeNervous system disorders0/1640/1630/1630/1631/720/305
Thrombotic cerebral infarctionNervous system disorders0/1640/1630/1630/1631/720/305
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlacebo (Weeks 0-24) Placebo-Controlled PhaseApremilast 20 mg BID (Weeks 0-24) Placebo-Controlled PhaseApremilast 30 mg BID (Weeks 0-24) Placebo-Controlled PhaseApremilast 20 mg BID (APR Exposure Period)Apremilast 20/30 mg BID (APR Exposure Period)Apremilast 30 mg BID (APR Exposure Period)
NasopharyngitisInfections and infestations6/1649/1637/16325/16310/7255/305
DiarrhoeaGastrointestinal disorders7/16422/16317/16326/1634/7238/305
Upper respiratory tract infectionInfections and infestations8/1647/1638/16317/1638/7232/305
HeadacheNervous system disorders8/1649/16316/16311/1635/7228/305
NauseaGastrointestinal disorders7/16410/16314/16313/1636/7228/305
BronchitisInfections and infestations1/1644/1632/1638/1636/7210/305
SinusitisInfections and infestations1/1642/1631/1637/1635/7210/305
HypertensionVascular disorders4/1644/1636/1636/1632/7221/305
IridocyclitisEye disorders0/1641/1631/1632/1634/728/305
Frequent bowel movementsGastrointestinal disorders2/1642/1633/1633/1634/723/305

Baseline characteristics

The modified Intent to Treat (mITT) population included all participants who were randomized and received at least one dose of investigational product (IP); Five participants did not have a baseline SF-36 Physical Component Summary score.

Age, Continuous
Age, Continuous(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean44.0 ± 12.8945.2 ± 11.9044.8 ± 11.7544.7 ± 12.18
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
Female404256138
Male124121107352
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
Hispanic or Latino5117
Not Hispanic or Latino158159162479
Unknown or Not Reported1304
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
American Indian or Alaska Native0000
Asian2204
Black or African American1225
Native Hawaiian or Other Pacific Islander1001
White158154158470
Other1236
Missing1304
Duration of Ankylosing Spondylitis (Lower Back Pain and Stiffness)
Duration of Ankylosing Spondylitis (Lower Back Pain and Stiffness)(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean10.40 ± 10.37511.06 ± 11.30210.32 ± 9.88710.60 ± 10.521
Duration of Ankylosing Spondylitis
Duration of Ankylosing Spondylitis(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
≤ 2 years414840129
>2 to ≤ 5 years29232678
>5 to ≤ 10 years33293395
>10 years616364188
Baseline Bath Ankylosing Spondylitis Functional Index (BASFI) Score (0 - 10 NRS)
Baseline Bath Ankylosing Spondylitis Functional Index (BASFI) Score (0 - 10 NRS)(Units on a Scale)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean5.76 ± 2.1945.75 ± 2.0615.65 ± 2.1005.72 ± 2.115
Baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (0 - 10 NRS)
Baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (0 - 10 NRS)(Units on a Scale)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean6.45 ± 1.3196.46 ± 1.3526.37 ± 1.3576.42 ± 1.341

3 further baseline measures are reported on the registry.

08

Study locations

103 sites
  • Sun Valley Arthritis Center
    Peoria, Arizona 85381, United States
  • University of California, San Diego
    La Jolla, California 92093-0943, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • UCSF Arthritis Center
    San Francisco, California 94143-0326, United States
  • Advent Clinical Research Centers, Inc
    Pinellas Park, Florida 33781, United States
  • Burnette & Silverfield, MDS PLC
    Tampa, Florida 33614, United States
  • Alastair Kennedy, MD Research
    Vero Beach, Florida 32960, United States
  • Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611, United States
  • Klein and Associates MD, PA
    Cumberland, Maryland 21502, United States
  • Klein and Associates MD, PA
    Hagerstown, Maryland 21740, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Saint Paul Rheumatology, PA
    Eagan, Minnesota 55121, United States
  • MetroHealth Medical Systems
    Cleveland, Ohio 44109, United States
  • STAT Research, Inc.
    Dayton, Ohio 45417, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • The Arthritis Clinic
    Jackson, Tennessee 38305, United States
  • Ramesh C Gupta MD
    Memphis, Tennessee 38119, United States
  • Austin Regional Clinic
    Austin, Texas 78731, United States
  • University of Utah Hospitals and Clinics
    Salt Lake City, Utah 84132, United States
  • Rheumatology and Immunotherapy Center
    Franklin, Wisconsin 53132, United States
  • Southern Clinical Research
    Hobart, Tasmania 7000, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Coastal Joint Care
    Maroochydore, 4558, Australia
  • Royal Perth Hospital
    Perth, 6849, Australia
  • The Queen Elizabeth Hospital
    Woodville South, 5011, Australia
  • Krankenhaus Wien-Hietzing
    Wien, 1130, Austria
  • Diagnostic and Consulting Center Sv. Pantaleymon
    Pleven, 5800, Bulgaria
  • National Multiprofile Transport Hospital Tzar Boris III
    Sofia, 1233, Bulgaria
  • 17 Diagnostic and Consulting Centre
    Sofia, 1505, Bulgaria
  • Military Medical Academy - MHAT
    Sofia, 1606, Bulgaria
  • Diagnostic Consulting Center N4
    Varna, 9010, Bulgaria
  • Clinic: University of Calgary Heritage Medical Research Clinic (HMRC),Teaching Research and Wellness (TRW)
    Calgary, Alberta T2N 4Z6, Canada
  • Nexus Clinical Research
    St John's, Newfoundland and Labrador A1A 5EB, Canada
  • Cividino Medicine Professional Corporation
    Hamilton, Ontario L8N 2B6, Canada
  • Dr. William G. Bensen Medicine Professional Corporation
    Hamilton, Ontario L8N1Y2, Canada
  • Credit Valley Professional Building
    Mississauga, Ontario L5M 2V8, Canada
  • The Arthritis Program Research Group Inc.
    Newmarket, Ontario L3Y 3R7, Canada
  • Rheumatology Research Associates
    Ottawa, Ontario K1H1A2, Canada
  • Toronto Western Hospital
    Toronto, Ontario M5T 258, Canada
  • Centre de Recherche Saint-Louis
    Saint-Louis, Quebec G1W 4R4, Canada
  • Revmatologie s.r.o.
    Brno, 638 00, Czechia
  • ARTMEDI UPD s.r.o.
    Hostivice, 253 01, Czechia
  • ARTHROMED s.r.o.
    Pardubice, 530 02, Czechia
  • Medifin a.s, Šustova
    Praha 11, 148 00, Czechia
  • Revmatologicka Ambulance
    Praha 4, 140 00, Czechia
  • Fakultni Thomayerova nemocnice s poliklinikou - Klinicko-farmakologicka jednotka
    Praha, 140 59, Czechia
  • Revmatologicka Ambulance
    Sokolov, 356 01, Czechia
  • PV-Medical s.r.o.
    Zlin, 760 01, Czechia
  • Innomedica Medical and Research Centre
    Tallinn, 10117, Estonia
  • East Tallinn Central Hospital
    Tallinn, 11412, Estonia
  • Clinical Research Centre Ltd
    Tartu, 50106, Estonia
  • Tartu University Hospital
    Tartu, 51014, Estonia
  • Hopital Ambroise-Pare
    Boulogne, 92100, France
  • Hopital Henri Mondor
    Créteil, 94010, France
  • IPROS - CHR ORLEANS - Hôpital de la Source
    Orléans Cedex 2, 45067, France
  • Hopital Cochin
    Paris, 75014, France
  • Groupe Hospitalier Pitié- Salpétrière
    Paris, 75651, France
  • Charite - Universitätsmedizin Berlin
    Berlin, 12203, Germany
  • Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
  • Centrum fur innovative Diagnostik und Therapie Rheumatologie Immunologie GmbH
    Frankfurt, 60528, Germany
  • Schön Klink Hamburg-Eilbek
    Hamburg, 22081, Germany
  • Universitatsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, 44649, Germany
  • Qualiclinic kft
    Budapest, 1036, Hungary
  • Synexus Magyarország Kft.
    Budapest, 1036, Hungary
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
    Debrecen, 4032, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Veszprem Megyei Csolnoky Ferenc Korhaz-Rendelointezet
    Veszprém, 8200, Hungary
  • Leiden Universitair Medisch Centrum
    Leiden, 2333 ZA, Netherlands
  • Academisch Ziekenhuis Maastricht
    Maastricht, 6229 HX, Netherlands
  • Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk
    Bialystok, 15-099, Poland
  • NZOZ Osteo-Medic sc A. Racewicz J. Supronik
    Bialystok, 15-351, Poland
  • Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Synexus SCM Sp. z o.o.
    Gdynia, 81-537, Poland
  • Zespol Poradni Specjalistycznych
    Lublin, 20-582, Poland
  • Prywatna Praktyka Lekarska Pawel Hrycaj
    Poznan, 61-397, Poland
  • NZOZ NASZ LEKARZ Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna
    Torun, 87-100, Poland
  • Synexus SCM Sp. z o.o.
    Wroclaw, 50-088, Poland
  • Cristei R. Rodica - Private Medical Practice
    Braila, 810019, Romania
  • Sf. Maria Clinical Hospital
    Bucharest, 011172, Romania
  • Emergency County Clinical Hospital
    Cluj-Napoca, 400006, Romania
  • Sf Apostol Andrei Emergency Clinical County Hospital
    Galati, 800578, Romania
  • RK Medcenter SRL
    Iasi, 700127, Romania
  • Sverdlovsk Regional Clinical Hospital 1
    Ekaterinburg, 620102, Russian Federation
  • Research Medical Complex Vashe Zdorovie
    Kazan, 420103, Russian Federation
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russian Federation
  • Federal State Budget Institution "Rheumatology Research Institute RAMS"
    Moscow, 115522, Russian Federation
  • Nizhniy Novgorod State Medical Academy of Roszdrav
    Nizhniy Novgorod, 603005, Russian Federation
  • Departmental Hospital at Smolensk Station RZhD JSC
    Smolensk, 214025, Russian Federation
  • Regional Clinical Hospital
    Vladimir, 600023, Russian Federation
  • Narodny ustav reumatickych chorob
    Piestany, 921 12, Slovakia
  • MUDr. Zuzana Cizmarikova, s.r.o., Reumatologick ambulancia
    Poprad, 058 01, Slovakia
  • Hospital Universitario a Coruna
    A Coruña, 15006, Spain
  • Hospital de Bellvitge
    Barcelona, 08907, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, 14001, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Corporacio Sanitaria Parc Tauli de Sabadell
    Sabadell, 08208, Spain
  • Complejo Hospitalario Universitario de Santiago de Compostela Travesía de la Choupana s/n
    Santiago de Compostela, 15706, Spain
  • Skånes Universitetssjukhus- Malmö
    Malmö, 20502, Sweden
  • Barnsley Hospital
    Barnsley, S75 2EP, United Kingdom

Showing the first 100 of 103 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018. PubMed 30018799 ↗
  • Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3. PubMed 31077258 ↗
  • Taylor PC, van der Heijde D, Landewe R, McCue S, Cheng S, Boonen A. A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. J Rheumatol. 2021 Aug;48(8):1259-1267. doi: 10.3899/jrheum.201088. Epub 2021 Feb 15. PubMed 33589554 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Feb 2014, 21 months.

Results were first posted in Mar 2015, 1 year after primary completion.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 21 months is close to that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2012
First posted
Apr 24, 2012
StartActual
May 2, 2012
Primary completionActual
Feb 24, 2014
CompletionActual
Oct 25, 2018
Results first posted
Mar 17, 2015
Last update
May 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01583374
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 24, 2012
Start date
May 2, 2012
Primary completion
Feb 24, 2014
Completion
Oct 25, 2018
Results posted
Mar 17, 2015
Last update
May 12, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion